Head-to-head evidence
GW642444M vs Salmeterol (DISKUS)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
GW642444M
Developed by GlaxoSmithKline
NCT00600171 · Phase 2 · completed
The study was randomized and double-blind, compared five GW642444M doses with placebo, and included 614 randomized participants. Its primary lung-function endpoint was a surrogate measure rather than a direct clinical outcome, and the results were mixed across doses: the 12.5, 25, and 50 microgram doses outperformed placebo, while the 3 and 6.25 microgram doses did not.
Salmeterol (DISKUS)
Marketed by GlaxoSmithKline
NCT00395304 · Phase 3 · completed
This was a rigorously designed, fully blinded, randomized crossover trial with a clinically meaningful composite primary measure, but the results available here do not show how the fluticasone-plus-salmeterol arm specifically compared with the other step-up therapies, so the salmeterol-specific effect cannot be confirmed from this data.
Next expected readout: June 2027 · NCT06676319 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GW642444M's landscape · Salmeterol (DISKUS)'s landscape